Medizinische Klinik III, Herzzentrum, Uniklinik Köln, Kerpener Str. 62, 50937, Cologne, Germany.
Clin Res Cardiol. 2018 Aug;107(Suppl 2):88-93. doi: 10.1007/s00392-018-1303-6. Epub 2018 Jun 27.
Percutaneous treatment of atrioventricular (AV) valve disease has long been restricted to therapy of mitral stenosis, and was only lately expanded to mitral regurgitation. 15 years ago the MitraClip edge to edge repair was first applied to human pathology. In Europe, German centers were the first to widely adopt this technique in patients with mitral regurgitation and high or inappropriate risk for surgery. Given the exponential rise in implantation procedures, expertise of the operators and investigator initiated investigations substantially contributed to improvements in procedural processes and patient selection. Meanwhile, additional techniques to repair the mitral and tricuspid valve were introduced to German interventionalists, both reconstructive techniques as well as first experiences with transcatheter implantation of mitral valve bioprostheses. Of note, specialized Heart Valve referral Centers catalyzed the adoption of these techniques. This review summarizes the contributions of German Heart Centers to recent developments in percutaneous therapy of AV valve disease.
经皮治疗房室（AV）瓣疾病长期以来一直仅限于二尖瓣狭窄的治疗，最近才扩展到二尖瓣反流。15 年前，MitraClip 边缘对边缘修复术首次应用于人体病理学。在欧洲，德国中心是最早在二尖瓣反流和手术高或不适当风险的患者中广泛采用该技术的中心。随着植入手术数量的指数级增长，术者的专业知识和研究者发起的研究为改善手术流程和患者选择做出了巨大贡献。与此同时，德国介入心脏病学家还引入了其他修复二尖瓣和三尖瓣的技术，包括重建技术以及经导管植入二尖瓣生物瓣的初步经验。值得注意的是，专门的心脏瓣膜转诊中心促进了这些技术的采用。本文综述了德国心脏中心对 AV 瓣疾病经皮治疗最新进展的贡献。
